glp 1 website GLP-1 Collective a Nonprofit Dedicated to Supporting the Community Discover How GLP-1 Trials Are

Measurement accuracy and reliability of self-reported versus measured weight and height among adults in Malaysia: findings from a nationwide blood pressure screening programme

In clinical trials, once-weekly semaglutide at diabetes doses (0.51 mg) produces mean weight loss of 46 kg (913 lbs), while the 2.4 mg dose (Wegovy) achieves average weight reductions of 1215% of body weight

86% of participants Achieved an A1c less than 7% Lost up to 11.2 kg (24.64 lbs) Trial #3 Compared tirzepatide with patients on metformin with/without SGLT-2 to degludec

[DOI] [PMC free article] [PubMed] [Google Scholar] 78.Bezin J, et al

These medicines may be prescribed off-label for weight loss, but there are also versions of the same drugs that are FDA-approved specifically for weight loss

Approximately 10% to 25% patients with NAFLD can progress to non-alcoholic steatohepatitis (NASH) and 10% to 15% patients with NASH develop hepatocellular carcinoma [2,3]